BullFrog AI Holdings, Inc., through its subsidiaries, operates as a digital biopharmaceutical company that focuses on artificial intelligence and machine learning (AI/ML) driven analysis of data sets in medicine and healthcare in the United States. It offers bfLEAP, an AI/ML platform for the analysis of preclinical and/or clinical data. The company also has licensing agreements with George Washington University for rights to use siRNA targeting Beta2-spectrin in the treatment of human diseases, including hepatocellular carcinoma, obesity, non-alcoholic fatty liver disease, and non-alcoholic steatohepatitis; and Johns Hopkins University for the use of a formulation of Mebendazole for the treatment of human cancer or neoplastic disease. BullFrog AI Holdings, Inc. was founded in 2017 and is based in Gaithersburg, Maryland.
Revenue of Bullfrog AI Holdings, Inc. Common Stock (BFRG)
Revenue in 2023 (TTM): $65 K
According to Bullfrog AI Holdings, Inc. Common Stock's latest financial reports the company's current revenue (TTM) is $65 K. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history of Bullfrog AI Holdings, Inc. Common Stock
Annual Revenue
| Year | Revenue | Gross Profit | Ebitda | Income Before Tax | Net Income |
|---|---|---|---|---|---|
| 2023 | $65 K | $58.08 K | $-5,365,800 | $-5,355,869 | $-5,355,869 |
| 2022 | $10 K | $9.2 K | $-2,454,297 | $-2,802,487 | $-2,802,487 |
| 2021 | $ | $ | $-555,362 | $-585,840 | $-585,840 |
| 2020 | $ | $ | $-347,193 | $-341,690 | $-341,690 |